|
|
Niklas Finnberg, Andres J.P. Klein-Szanto, Wafik S. El-Deiry
J Clin Invest. 2008;
118(1):111
doi:10.1172/JCI29900
Abstract |
Full text
| PDF
| Supplemental material

P
reclinical data support the potential of the death-signaling receptors for TRAIL as targets for cancer therapy. However, it is unclear whether these death-signaling receptors suppress the emergence and growth of malignant tumors in vivo. Herein we show that TNF-related apoptosis-inducing ligand receptor (TRAIL-R), the only proapoptotic death-signaling receptor for TRAIL in the mouse, suppresses inflammation and tumorigenesis. Loss of a single TRAIL-R allele on the lymphoma-prone Eμ-myc genetic background significantly reduced median lymphoma-free survival. TRAIL-R–deficient lymphomas developed with equal frequency irrespective of mono- or biallelic loss of TRAIL-R, had increased metastatic potential, and showed apoptotic defects relative to WT littermates. In addition, TRAIL-R–/– mice showed decreased long-term survival following a sublethal dose of ionizing radiation. Histological evaluation of moribund irradiated TRAIL-R–/– animals showed hallmarks of bronchopneumonia as well as tumor formation with increased NF-κB p65 expression. TRAIL-R also suppressed diethylnitrosamine-induced (DEN-induced) hepatocarcinogenesis, as an increased number of large tumors with apoptotic defects developed in the livers of DEN-treated TRAIL-R–/– mice. Thus TRAIL-R may function as an inflammation and tumor suppressor in multiple tissues in vivo.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(30)
| Title and authors |
Publication |
Year |
Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells
Y Oh, Y-J Jeon, G-S Hong, I Kim, H-N Woo, Y-K Jung
|
Cell Death Differ
|
2012 |
Deconstructing p53 transcriptional networks in tumor suppression
Kathryn T. Bieging, Laura D. Attardi
|
Trends in Cell Biology
|
2012 |
Resistance to TRAIL and how to surmount it
Danijela Maksimovic-Ivanic, Stanislava Stosic-Grujicic, Ferdinando Nicoletti, Sanja Mijatovic
|
Immunol Res
|
2012 |
Sensitization to TRAIL-induced apoptosis in human neuroblastoma SK-N-AS cells by NF-κB inhibitors is dependent on reactive oxygen species (ROS)
Tom Gatsinzi, Kerstin Iverfeldt
|
J Neurooncol
|
2011 |
Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
Pamela M. Holland
|
Cancer Letters
|
2011 |
Targeting the extrinsic apoptosis signaling pathway for cancer therapy
Thomas J. Sayers
|
Cancer Immunol Immunother
|
2011 |
Targeted expression of tumor necrosis factor-related apoptosis-inducing ligand TRAIL in skin protects mice against chemical carcinogenesis
Valerie Kedinger, Stephanie Muller, Hinrich Gronemeyer
|
Mol Cancer
|
2011 |
Natural Innate and Adaptive Immunity to Cancer
Matthew D. Vesely, Michael H. Kershaw, Robert D. Schreiber, Mark J. Smyth
|
Annu. Rev. Immunol.
|
2011 |
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis
Curtis J. Henrich, Cheryl L. Thomas, Alan D. Brooks, Nancy Lynn Booth, Evan M. Lowery, Richard J. Pompei, James B. McMahon, Thomas J. Sayers
|
Apoptosis
|
2011 |
Enhancing apoptosis in TRAIL-resistant cancer cells using fundamental response rules
Vincent Piras, Kentaro Hayashi, Masaru Tomita, Kumar Selvarajoo
|
Sci. Rep.
|
2011 |
|